ACRX up +12.11% percent right now. $ACRX High is at 7.04 and the Low 5.93 with current volume of 1,835,095.
Recent News posted below.
ACRX Acelrx Pharmaceuticals Recent Headline News
AcelRx Pharmaceuticals (ACRX) Stock Rises After Third-Quarter Earnings Report
at The Street - Tue Nov 11, 11:00AM CST
Shares of AcelRx Pharmaceuticals (ACRX) surged in late morning trading Tuesday after the company reported third-quarter results after the market close Monday that beat analysts' expectations.
ACRX: 6.92 (+0.89)
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
ACRX: 6.92 (+0.89), AAWW: 41.69 (-0.06), JOBS: 34.59 (+0.13), AKRX: 35.14 (-1.02), ADVS: 33.24 (-0.21)
Regulus Slumps: RGLS Falls 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:53AM CST
Regulus has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past 24 hours
ACRX: 6.92 (+0.89), AUXL: 32.61 (-0.09), ADHD: 3.65 (-0.02), RGLS: 20.29 (-0.62)
ArQule (ARQL) Catches Eye: Stock Jumps 10.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:30AM CST
ArQule Inc. (ARQL) was a big mover last session, as the company saw its shares rise over 10% on the day.
ACRX: 6.92 (+0.89), AUXL: 32.61 (-0.09), ADHD: 3.65 (-0.02), ARQL: 1.17 (unch)
AcelRx revises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:34AM CST
ACRX: 6.92 (+0.89)
AcelRx Pharmaceuticals (ACRX) CEO Richard King on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 10:17PM CST
ACRX: 6.92 (+0.89)
AcelRx Pharmaceuticals beats by $0.09, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:03PM CST
ACRX: 6.92 (+0.89)
AcelRx Pharmaceuticals Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:01PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and nine months ended September 30, 2014.
ACRX: 6.92 (+0.89)
OTC Daily Alert Stock Watch - AcelRx Pharmaceuticals, Inc (NASDAQ: ACRX)
WorldStockWire - Mon Nov 10, 12:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ACRX: 6.92 (+0.89)
AcelRx Pharmaceuticals Receives International Standards Organization (ISO) 13485:2003 Certification of its Quality Management System
PR Newswire - Mon Nov 10, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has been granted International Standards Organization (ISO) 13485:2003 certification of its quality management system, an internationally recognized quality standard for medical devices issued by the British Standards Institution (BSI).
ACRX: 6.92 (+0.89)
AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events
PR Newswire - Fri Nov 07, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be presenting at the Credit Suisse Annual Healthcare Conference and Jefferies Global Healthcare Conference. Details of the two events are as follows:
ACRX: 6.92 (+0.89)
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.
Business Wire - Thu Nov 06, 2:34PM CST
Glancy Binkow & Goldberg LLP reminds investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company"
(NASDAQ: ACRX) that those who purchased or otherwise acquired AcelRx's common stock and/or call options, or sold/wrote AcelRx's put options between December 2, 2013 and September 25, 2014, inclusive (the "Class Period" , have until December 1, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the Northern District of California.
ACRX: 6.92 (+0.89)
AcelRx chief bids adieu
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 12:34PM CST
ACRX: 6.92 (+0.89)
AcelRx Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Monday, November 10, 2014
PR Newswire - Thu Nov 06, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release third quarter 2014 financial results after market close on Monday, November 10th, 2014. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on November 10, 2014 to discuss the financial results and provide a corporate update.
ACRX: 6.92 (+0.89)
Acelrx Pharmaceuticals Announces Management Change
PR Newswire - Wed Nov 05, 3:00PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the departure of Richard King, the Company's CEO and President. The Board of Directors has initiated a CEO search and Mr. King will remain with the Company as President and Chief Executive Officer while the search is ongoing and during this transition period.
ACRX: 6.92 (+0.89)
Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.92 (+0.89), PTX: 11.21 (+1.30), AKRX: 35.14 (-1.02), RPRX: 9.78 (+0.56), NKTR: 13.82 (+0.03)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $50,000 Investing in AcelRx Pharmaceuticals, Inc. (ACRX) to Contact the Firm
GlobeNewswire - Fri Oct 31, 4:23PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company" (Nasdaq:ACRX) of the December 1, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against AcelRx and certain executives.
ACRX: 6.92 (+0.89)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in AcelRx Pharmaceuticals, Inc. to Contact Brower Piven Before the December 1, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- ACRX
GlobeNewswire - Wed Oct 29, 12:05PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company" (Nasdaq:ACRX) common stock and/or call options, or sold/wrote AcelRx's put options between December 2, 2013 and September 25, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until December 1, 2014 to seek appointment as lead plaintiff.
ACRX: 6.92 (+0.89)
Can The Uptrend Continue for AcelRx Pharmaceuticals (ACRX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:52AM CDT
Can The Uptrend Continue for AcelRx Pharmaceuticals (ACRX)?
ACRX: 6.92 (+0.89)
Commit To Purchase AcelRx Pharmaceuticals At $5, Earn 15.5% Annualized Using Options
StockOptionsChannel.com - Mon Oct 27, 10:28AM CDT
Investors eyeing a purchase of AcelRx Pharmaceuticals Inc shares, but cautious about paying the going market price of $6.74/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
ACRX: 6.92 (+0.89)
Recent News posted below.
ACRX Acelrx Pharmaceuticals Recent Headline News
AcelRx Pharmaceuticals (ACRX) Stock Rises After Third-Quarter Earnings Report
at The Street - Tue Nov 11, 11:00AM CST
Shares of AcelRx Pharmaceuticals (ACRX) surged in late morning trading Tuesday after the company reported third-quarter results after the market close Monday that beat analysts' expectations.
ACRX: 6.92 (+0.89)
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
ACRX: 6.92 (+0.89), AAWW: 41.69 (-0.06), JOBS: 34.59 (+0.13), AKRX: 35.14 (-1.02), ADVS: 33.24 (-0.21)
Regulus Slumps: RGLS Falls 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:53AM CST
Regulus has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past 24 hours
ACRX: 6.92 (+0.89), AUXL: 32.61 (-0.09), ADHD: 3.65 (-0.02), RGLS: 20.29 (-0.62)
ArQule (ARQL) Catches Eye: Stock Jumps 10.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:30AM CST
ArQule Inc. (ARQL) was a big mover last session, as the company saw its shares rise over 10% on the day.
ACRX: 6.92 (+0.89), AUXL: 32.61 (-0.09), ADHD: 3.65 (-0.02), ARQL: 1.17 (unch)
AcelRx revises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:34AM CST
ACRX: 6.92 (+0.89)
AcelRx Pharmaceuticals (ACRX) CEO Richard King on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 10:17PM CST
ACRX: 6.92 (+0.89)
AcelRx Pharmaceuticals beats by $0.09, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:03PM CST
ACRX: 6.92 (+0.89)
AcelRx Pharmaceuticals Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:01PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and nine months ended September 30, 2014.
ACRX: 6.92 (+0.89)
OTC Daily Alert Stock Watch - AcelRx Pharmaceuticals, Inc (NASDAQ: ACRX)
WorldStockWire - Mon Nov 10, 12:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ACRX: 6.92 (+0.89)
AcelRx Pharmaceuticals Receives International Standards Organization (ISO) 13485:2003 Certification of its Quality Management System
PR Newswire - Mon Nov 10, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has been granted International Standards Organization (ISO) 13485:2003 certification of its quality management system, an internationally recognized quality standard for medical devices issued by the British Standards Institution (BSI).
ACRX: 6.92 (+0.89)
AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events
PR Newswire - Fri Nov 07, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be presenting at the Credit Suisse Annual Healthcare Conference and Jefferies Global Healthcare Conference. Details of the two events are as follows:
ACRX: 6.92 (+0.89)
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc.
Business Wire - Thu Nov 06, 2:34PM CST
Glancy Binkow & Goldberg LLP reminds investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company"
(NASDAQ: ACRX) that those who purchased or otherwise acquired AcelRx's common stock and/or call options, or sold/wrote AcelRx's put options between December 2, 2013 and September 25, 2014, inclusive (the "Class Period" , have until December 1, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the Northern District of California. ACRX: 6.92 (+0.89)
AcelRx chief bids adieu
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 12:34PM CST
ACRX: 6.92 (+0.89)
AcelRx Pharmaceuticals to Hold Third Quarter Financial Results Conference Call and Webcast on Monday, November 10, 2014
PR Newswire - Thu Nov 06, 6:00AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release third quarter 2014 financial results after market close on Monday, November 10th, 2014. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on November 10, 2014 to discuss the financial results and provide a corporate update.
ACRX: 6.92 (+0.89)
Acelrx Pharmaceuticals Announces Management Change
PR Newswire - Wed Nov 05, 3:00PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the departure of Richard King, the Company's CEO and President. The Board of Directors has initiated a CEO search and Mr. King will remain with the Company as President and Chief Executive Officer while the search is ongoing and during this transition period.
ACRX: 6.92 (+0.89)
Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.92 (+0.89), PTX: 11.21 (+1.30), AKRX: 35.14 (-1.02), RPRX: 9.78 (+0.56), NKTR: 13.82 (+0.03)
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $50,000 Investing in AcelRx Pharmaceuticals, Inc. (ACRX) to Contact the Firm
GlobeNewswire - Fri Oct 31, 4:23PM CDT
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company"
(Nasdaq:ACRX) of the December 1, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against AcelRx and certain executives. ACRX: 6.92 (+0.89)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in AcelRx Pharmaceuticals, Inc. to Contact Brower Piven Before the December 1, 2014 Lead Plaintiff Deadline in Class Action Lawsuit -- ACRX
GlobeNewswire - Wed Oct 29, 12:05PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf of purchasers of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company"
(Nasdaq:ACRX) common stock and/or call options, or sold/wrote AcelRx's put options between December 2, 2013 and September 25, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until December 1, 2014 to seek appointment as lead plaintiff. ACRX: 6.92 (+0.89)
Can The Uptrend Continue for AcelRx Pharmaceuticals (ACRX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:52AM CDT
Can The Uptrend Continue for AcelRx Pharmaceuticals (ACRX)?
ACRX: 6.92 (+0.89)
Commit To Purchase AcelRx Pharmaceuticals At $5, Earn 15.5% Annualized Using Options
StockOptionsChannel.com - Mon Oct 27, 10:28AM CDT
Investors eyeing a purchase of AcelRx Pharmaceuticals Inc shares, but cautious about paying the going market price of $6.74/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
ACRX: 6.92 (+0.89)
